INTELLIGENT BIO SOLUTIONS INC近日公布业绩预告,公司2026财年第二季度营收预计将实现约48%的同比增长。这一强劲增长势头推动其2026财年上半年总营收突破200万美元大关,彰显出公司业务发展的显著加速。
业绩预增主要得益于公司在生物传感技术领域的持续创新与市场拓展。相较于去年同期,本财季的营收表现反映出其核心产品商业化进程的深化及全球客户基础的扩大。上半年累计营收的超预期达成,进一步巩固了公司在医疗诊断细分领域的竞争地位。
INTELLIGENT BIO SOLUTIONS INC近日公布业绩预告,公司2026财年第二季度营收预计将实现约48%的同比增长。这一强劲增长势头推动其2026财年上半年总营收突破200万美元大关,彰显出公司业务发展的显著加速。
业绩预增主要得益于公司在生物传感技术领域的持续创新与市场拓展。相较于去年同期,本财季的营收表现反映出其核心产品商业化进程的深化及全球客户基础的扩大。上半年累计营收的超预期达成,进一步巩固了公司在医疗诊断细分领域的竞争地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.